NASDAQ · CLBT
Cellebrite DI financials
$11.07+2.60%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Diluted shares | 249.9M | 209.5M | 190.2M | 195.4M | 161.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $124.5M | $191.7M | $189.5M | $87.6M | $146.0M |
| Short-term investments | $151.5M | $101.8M | $38.7M | $44.6M | $35.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $938.9M | $690.6M | $532.9M | $403.3M | $339.8M |
| Total liabilities | $454.5M | $354.5M | $498.7M | $329.4M | $413.1M |
| Shareholders' equity | $484.3M | $336.0M | $34.2M | $73.9M | -$73.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology